Nasus Pharma is trading 5.04% down at $3.20 after closing the regular session at $3.37, with no company-specific catalyst identified.
- Searches found no announcement, filing, earnings release, analyst action, or other direct catalyst explaining the decline.
- Broader markets were generally stronger on August 13, 2026, supported by softer inflation data and reduced rate-hike expectations.
- The movement appears isolated, and its cause remains unclear.